Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

M. J. Hepburn; M. G. Kortepeter; P. R. Pittman; E. F. Boudreau; J. A. Mangiafico; P. A. Buck; S. L. Norris; E. L. Anderson

doi:10.1016/j.vaccine.2005.12.055

Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

M. J. Hepburn^*, M. G. Kortepeter, P. R. Pittman, E. F. Boudreau, J. A. Mangiafico, P. A. Buck, S. L. Norris, E. L. Anderson

^*Corresponding author for this work

Preventive Medicine and Biostatistics

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p < 0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.

Original language	English
Pages (from-to)	2843-2849
Number of pages	7
Journal	Vaccine
Volume	24
Issue number	15
DOIs	https://doi.org/10.1016/j.vaccine.2005.12.055
State	Published - 5 Apr 2006

Keywords

Booster
Neutralizing antibody
Yellow fever vaccine

Access to Document

10.1016/j.vaccine.2005.12.055

Cite this

@article{9ba9b65860d949228cdd070cca00c599,

title = "Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine",

abstract = "A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p < 0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.",

keywords = "Booster, Neutralizing antibody, Yellow fever vaccine",

author = "Hepburn, {M. J.} and Kortepeter, {M. G.} and Pittman, {P. R.} and Boudreau, {E. F.} and Mangiafico, {J. A.} and Buck, {P. A.} and Norris, {S. L.} and Anderson, {E. L.}",

year = "2006",

month = apr,

day = "5",

doi = "10.1016/j.vaccine.2005.12.055",

language = "English",

volume = "24",

pages = "2843--2849",

journal = "Vaccine",

issn = "0264-410X",

number = "15",

}

TY - JOUR

T1 - Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

AU - Hepburn, M. J.

AU - Kortepeter, M. G.

AU - Pittman, P. R.

AU - Boudreau, E. F.

AU - Mangiafico, J. A.

AU - Buck, P. A.

AU - Norris, S. L.

AU - Anderson, E. L.

PY - 2006/4/5

Y1 - 2006/4/5

N2 - A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p < 0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.

AB - A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p < 0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.

KW - Booster

KW - Neutralizing antibody

KW - Yellow fever vaccine

UR - http://www.scopus.com/inward/record.url?scp=33644923779&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.12.055

DO - 10.1016/j.vaccine.2005.12.055

M3 - Article

C2 - 16494976

AN - SCOPUS:33644923779

SN - 0264-410X

VL - 24

SP - 2843

EP - 2849

JO - Vaccine

JF - Vaccine

IS - 15

ER -

Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

Abstract

Keywords

Access to Document

Fingerprint

Cite this